Subsidies & Funding

We empower medical innovation

Project Management

We manage research & innovation projects

Business Strategy

We support successful commercialisation


Other EU Subsidies

Wellcome Trust's vision is to achieve extraordinary improvements in human and animal health. In pursuit of this, they support the brightest minds in biomedical research and the medical humanities. In the 2012/2013 financial year, Wellcome Trust funded 927 new grants and 235 supplementary / enhancement grants with a total value of £559M (€ 705M), over 85%  of which went to science funding. The award rate (number of awards divided by number of applications) between 2008 and 2013 has been between 20 and 25%.

Areas of research

Wellcome Trust has identified five major challenge areas for the 2010 - 2020 period. Funding from the past four years has been divided over these areas as follows:

  • Genetics and genomics - £ 240M / 9.2%
  • Understanding the brain - £ 474M / 18.2%
  • Combating infectious disease - £ 568M / 21.8%
  • Development, ageing and chronic disease - £ 868M / 33.4%
  • Environment, nutrition and health - £ 28M / 1.1%
  • Cross-challenge - £ 423M / 16.3%

Biomedical science grant applications

Selected biomedical science grants are listed in the tables below.

Business grants

  • Translational Fund (500k - 5M)
  • Seeding Drug Discovery (1 - 2M)
  • Health Innovation Fund
  • Pathfinder Award (100k - 350k)

Academic grants

  • Investigator Awards (3M)
  • Seed Awards (100k)
  • Fellowships (salary + bench fee)
  • Collaborative Awards (4M)

Additionally, varying strategic awards and themed initiatives are offered, which may be found here.

An extensive grant deadlines calendar is provided here.

Eligible applicants for academic research grants are based at higher education or research institutions in the UK, Ireland or low- or middle-income countries. Companies that apply for innovation research have to be based in the UK, but collaborations with international partners are allowed.

Funding framework

(from the Wellcome Trust website)

Strategic funding is available in research areas that we judge to be strategically important, informed by dialogue with our researchers and the wider community. Applications will be invited, but we welcome the opportunity to discuss research ideas that might fit with our strategic priorities, and that might be suitable for an invitation. Final awards under our current Strategic Awards scheme will be made in July 2015.

Responsive funding, which represents the majority, is divided into five categories that run across our Science, Innovations, Medical Humanities, Society and Ethics, and Engaging Science funding.

The five categories are people, seeds, teams, places and resources.


We believe that breakthroughs emerge when talented researchers are given the resources and freedom they need to pursue their goals. We will continue to offer personal support to researchers through schemes such as Investigator Awards and fellowships.

Our New Investigator and Senior Investigator Award schemes have been merged into single Investigator Award schemes specific to Science, Medical Humanities or Society and Ethics. All candidates will continue to be considered according to their career stage and experience to date.

We have increased funding opportunities available through our Sir Henry Wellcome Postdoctoral Fellowship and Sir Henry Dale Fellowship schemes.


This is a new kind of funding to support the generation of new ideas. It aims to address a gap identified by our community: small awards to investigate riskier concepts.

Seed Awards in Science, Medical Humanities and Society and Ethics provide funding to develop original and innovative ideas, enabling researchers to generate preliminary data, resources, networks, tools or archival research towards a larger research application.

In Innovations, our updated Pathfinder Awards offer pilot funding to catalyse innovative early-stage applied research and development projects in areas of unmet medical need to develop assets and de-risk future development.

Within public engagement, we offer seed funding through our Development Awards (Broadcast, Games and Film) and we have increased the cap on seed funding available through our People Awards and Small Arts Awards.


We recognise that collaboration is a key component of a vibrant research environment. It promotes the development of new ideas and can bring different disciplines together to speed up the pace of discovery. We have developed a new kind of funding for collaborative research.

Collaborative Awards in Science, Medical Humanities and Society and Ethics provide groups of researchers with the support to pursue key research questions where a team effort is required.

Portfolio Awards support collaborative research and technology development by funding programmes which require a portfolio of projects to deliver leading-edge innovations in healthcare.

The call for Collaborative Awards will open in the new year.

We continue to support innovative projects that engage and involve the public with biomedical science through existing programmes and our new Sustaining Excellence Awards, which support the enhanced delivery of outstanding public engagement work.


To ensure that researchers can work and train in world-class environments, we continue to provide long-term support for centres of excellence in the UK and in low- and middle-income countries.


This support provides funding for shared equipment, facilities and research resources, including support for longitudinal studies.

ttopstart can help you apply for funding at Wellcome Trust

ttopstart has extensive experience in the support of applications for complex subsidy programmes such as that of the Wellcome Trust. ttopstart can help identify a program and funding opportunity and perform a thorough feasibility assessment prior to preparing a full application. Our services for Wellcome Trust subsidies are largely comparable to those of Horizon 2020. Please contact us for more information.


ir. Jasper Levink

The Innovative Medicines Initiative (IMI) is a collaboration between the European Union and the European pharmaceutical industry, and it is currently in its second phase (IMI2). This phase, following Horizon 2020 and lasting from 2014-2020, has a remaining budget of almost €3.3 billion to fund life sciences research.

About the Innovative Medicines Initiative

Represented by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), the European Union and its pharmaceutical industry aim to improve health. This is achieved by speeding up the development of (and patient access to) innovative medicines like vaccines, medicines and treatments.

Importantly, IMI2 is all about collaboration between key players in life sciences research and includes not only knowledge institutes (like universities or research centres) and pharmaceutical companies, but also SMEs, patient organisations, and medicines regulators. A total budget of €3.276 billion is available. So far, a total of 90 projects, with 868 participants have been funded.

Strategic Research Agenda (SRA)

The general aim of IMI2 is to deliver “the right prevention and treatment for the right patient at the right time”. In order to stay focused, specific priority disease areas have been defined. This way, the greatest possible impact is achieved.

Overarching the priority diseases, four main axes of research have been defined:

  1. Target validation and biomarker research (efficacy and safety);
  2. Adoption of innovative clinical trial paradigms;
  3. Innovative medicines;
  4. Patient-tailored adherence programmes.

IMI2 grants

Why apply for IMI2?

IMI2 is the largest public-private partnership (PPP) of Europe in the life sciences. Consortia are usually granted between €1 and €25 million! IMI2 projects deliver the highest-quality research, which is reflected by the citation impact that is nearly twice the EU average. By applying for an IMI2 grant, you are applying for a diverse international community with different types of key players in the life sciences.

Application process

Most IMI2 calls follow a two-stage application process. After the call text has been published, there is a pre-proposal application deadline that allow you to form a consortium and submit a short proposal. Next, only the top-rated application per topic are invited to form a full consortium together with the EFPIA/Associated Partner consortium behind that topic and prepare the full proposal. Conveniently, IMI2 usually publishes future topics early on, which gives you the opportunity to start forming your idea and consortium early too.

IMI2 calls

Most recently, call 18 and 19 have started, with calls on a variety of topics. The deadline for pre-proposals for these topics is September 26, 2019. Full proposals are due March 26, 2020. Stay updated on all current calls of IMI2 in our Life Sciences Funding Database

Request assistance

Thinking about applying for an IMI2 grant? ttopstart can support you! We have extensive experience and have supported several successful IMI proposals. Contact us today to find out what we can do for you.


ir. Jasper Levink

The European Investment Bank (EIB) is the biggest multilateral borrower and lender of the world, and aims to improve the quality of life for people in Europe and beyond.

About the European Investment Bank Group

The European Investment Bank was founded in Brussels in 1958. 90% of its activities are in Europe, although since 1960 partnerships have been established with countries outside the EU. With EU Member States as its shareholders, the EIB provides finance for sustainable investment projects that should contribute to objectives posed by EU policy.

EIB's activities take place in its four main priorities: innovation and skills, small and medium enterprises, infrastructure, and environment. General objective in all priorities is to support both job creation as well as sustainable growth. The EIB supports a wide range of sectors, including "Health and life science", "Agriculture, food and rural development" and more.


Lending is EIB's main activity. Financing here includes loans (project and intermediated), microfinance, venture capital, and equity and fund investment. The money that EIB lends is acquired through bond issues, and due to its outstanding credit rating this results in good rates for its borrowers. Typically, around one-third of total project costs can be financed through EIB lending. Usually, the support by the EIB is the first step in attracting other investors, thereby creating a multiplier effect.


Blending is a combination of EIB loans or services with funding opportunities from other resources, in order to provide a full financing service. For example, Blending can help projects that otherwise would have a risk profile that is too high. Blending forms are partly provided by the European Investment Fund (EIF), which has expertise in SME finance.

There are many different types of blended financing. Examples of these are guarantees, projects bonds, trust funds and many more. InnovFin is an example of a Blending form, that is of special interest to Life Science entrepreneurs through InnovFin Infectious Diseases.


In order to complement the Lending activities, the EIB also offers advisory services through the European Investment Advisory Hub – which aims to ensure improved knowledge sharing as well as guidance to the right people for your project specifically. Both technical and financial expertise is made available, which in turn can strengthen the technical and economic foundations of an investment.

Request assistance

ttopstart can support your applications to the EIB. Contact us today to find out the possibilities.